Dashboard
Manage Tickers

BCRX BIOCRYST PHARMACEUTICALS INC

Nasdaq biocryst.com


$ 6.81 $ 0.39 (6.07 %)    

Wednesday, 15-Oct-2025 19:25:33 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.35 $ 4.22 (0.71 %)
DIA $ 462.89 $ 0.00 (0 %)
SPY $ 665.02 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.19 $ 6.60 (1.73 %)
$ 6.81
$ 6.53
$ 6.79 x 500
$ 6.84 x 75
$ 6.46 - $ 6.88
$ 6.00 - $ 11.31
15,794,221
na
1.43B
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-13-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-08-2017 03-31-2017 10-Q
35 02-27-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

td-cowen-reinstates-buy-on-biocryst-pharma-announces-30-price-target
TD Cowen Reinstates Buy on BioCryst Pharma...
10/15/2025 14:15:07

TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.

cantor-fitzgerald-maintains-overweight-on-biocryst-pharma-raises-price-target-to-26
Cantor Fitzgerald Maintains Overweight on ...
10/15/2025 14:11:32

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overweight and raises the price ta...

jmp-securities-maintains-market-outperform-on-biocryst-pharma-raises-price-target-to-27
JMP Securities Maintains Market Outperform...
10/15/2025 11:21:33

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

needham-maintains-buy-on-biocryst-pharma-raises-price-target-to-20
Needham Maintains Buy on BioCryst Pharma, ...
10/15/2025 10:00:17

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $17 to $20.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate
BioCryst Says Astria Therapeutics $700 Mil...
10/14/2025 16:20:52

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

trading-halt-halt-status-updated-at-71500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:15:...
10/14/2025 11:15:04

Core News & Articles
BioCryst to Acquire Astria Therapeutics fo...
10/14/2025 11:02:17

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
10/14/2025 10:55:04

biocryst-pharmaceuticals-and-biocryst-ireland-entered-into-a-trademark-license-agreement
BioCryst Pharmaceuticals And Biocryst Irel...
10/01/2025 13:37:47

-SEC Filing

ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder
Ionis Pharma Wins FDA Nod For First RNA-Ta...
08/21/2025 18:24:53

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...

needham-maintains-buy-on-biocryst-pharma-maintains-17-price-target
Needham Maintains Buy on BioCryst Pharma, ...
08/04/2025 22:11:09

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $17 price target.

biocryst-pharma-maintains-fy25-outlook-for-global-net-orladeyo-revenue-between-580m-and-600m
BioCryst Pharma Maintains FY25 Outlook For...
08/04/2025 11:05:04

Financial Outlook for 2025The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between $580...

biocryst-pharma-q2-eps-002-misses-004-estimate-sales-163353m-beat-149530m-estimate
BioCryst Pharma Q2 EPS $0.02 Misses $0.04 ...
08/04/2025 11:01:10

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0....

Core News & Articles
Earnings Scheduled For August 4, 2025
08/04/2025 08:32:29

earnings-outlook-for-biocryst-pharma
Earnings Outlook For BioCryst Pharma
08/01/2025 19:05:13

biocryst-pharmaceuticals-president-and-ceo-jon-stonehouse-will-retire-on-december-31-the-company-has-appointed-charlie-gayer-currently-the-companys-chief-commercial-officer-as-the-next-president-effective-august-1-and-next-ceo-effective-january-1-2026
BioCryst Pharmaceuticals' President And CE...
07/31/2025 11:17:29

biocryst-pharmaceuticals-appoints-babar-ghias-as-chief-financial-officer-and-head-of-corporate-development
BioCryst Pharmaceuticals Appoints Babar Gh...
07/07/2025 11:02:09

b-of-a-securities-maintains-buy-on-biocryst-pharma-raises-price-target-to-15
B of A Securities Maintains Buy on BioCrys...
07/01/2025 13:44:30

B of A Securities analyst Tazeen Ahmad maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $...

rbc-capital-reiterates-outperform-on-biocryst-pharma-maintains-13-price-target
RBC Capital Reiterates Outperform on BioCr...
06/30/2025 14:04:24

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $13 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION